Business & regional news

New 11-bed facility at Apollo Jubilee Hills to feature integrated Acute Care & Monitoring technologies and serve as a real-world clinical innovation hub for Medtronic R&D.

New, enhanced visualization†, seamless streaming, retrospective recording, and other advanced features to support the clinical need to intubate with first-pass success^‡,1,2

Following recent U.S. FDA clearance, Medtronic expands access to its next-generation ENT navigation platform across Europe

The FDA cleared multi-parameter wearable designed for continuous monitoring of vital signs enhances the Acute Care & Monitoring portfolio of patient monitoring solutions.

SINGAPORE, [May 25, 2026] – Medtronic plc, a global leader in healthcare technology, announced that Medtronic Singapore and the Society of Colorectal Surgeons, Singapore (SCRS) have signed a...

Newly published insights from the ALLEVIATE-HF clinical trial found a high rate of actionable arrhythmias in heart failure patients, leading to therapeutic intervention

EuroPCR Hot Line Science features positive outcomes from the largest international head-to-head comparative trial of TAVR

First cases successfully performed by Rahul Patel, MD, at The Mount Sinai Hospital, NY, and Gloria Salazar, MD, UNC Hospitals, Chapel Hill

New VitalFlow Transport Frame AG advances care for transport for ECMO patients between medical facilities

Company recognized as one of the 10 most influential in health and life sciences category

First procedure performed at Axia Women’s Health by Dr. Vincent R. Lucente

Next generation mitral valve, designed to facilitate patient lifetime management and setting new benchmark for ease of use in small incision surgery1-3 reports first uses in sternotomy, Minimally Invasive Cardiac Surgery (MICS) and robotic cases

Recognition highlights Medtronic as a leading workplace for career growth across key European markets

Heart Rhythm 2026: Real-world outcomes reinforce Aurora EV-ICD system as a reliable option for indicated patients requiring protection from dangerously fast heart rhythms

Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population¹